➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Moodys
McKesson
Express Scripts
Baxter

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,153,689

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,153,689 protect, and when does it expire?

Patent 8,153,689 protects XENLETA and is included in two NDAs.

This patent has thirty-eight patent family members in twenty-six countries.

Summary for Patent: 8,153,689
Title:Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Abstract: Disclosed are pleuromutilin derivatives of formula (I) ##STR00001## and their use in the treatment of diseases mediated by microbes.
Inventor(s): Mang; Rosemarie (Vienna, AT), Heilmayer; Werner (Zillingtal, AT), Badegruber; Rudolf (Vienna, AT), Strickmann; Dirk B. (Vienna, AT), Novak; Rodger (Vienna, AT), Ferencic; Mathias (Vienna, AT), Bulusu; Atchyuta Rama Chandra Murty (Perchtoldsdorf, AT)
Assignee: Nabriva Therapeutics AG (Vienna, AT)
Application Number:13/252,732
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,153,689

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Nabriva XENLETA lefamulin acetate SOLUTION;INTRAVENOUS 211673-001 Aug 19, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Nabriva XENLETA lefamulin acetate TABLET;ORAL 211672-001 Aug 19, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,153,689

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07450053Mar 20, 2007

International Family Members for US Patent 8,153,689

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 523486   Start Trial
Australia 2008229609   Start Trial
Brazil PI0809023   Start Trial
Canada 2678795   Start Trial
China 101668738   Start Trial
China 104211624   Start Trial
Cyprus 1117482   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Baxter
Merck
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.